 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 164
Date: May 26, 2024
Our hypothetical patient “Harvey” is back from the U.K., where he underwent “compassionate use” therapy with the new fully humanized monoclonal antibody HuMax-CD20. You can see how our intrepid hero fared with the new therapy in our new article Genmab in the News.
Genmab’s HuMax-CD20 is going to be an important drug for CLL patients. It has been fast-tracked for that application by the FDA, and someday soon it may really give Rituxan a run for its money. The fact that it is a fully humanized monoclonal may give it advantages over the chimeric (half-mouse, half-human protein) Rituxan, in terms of allergic reactions and the like. Genmab has just announced a large Phase-3 clinical trial of their drug, and we have reviewed their trial protocol as well in this article. You can bet we will be following this new trial closely, and keeping touch with the company behind the drug. Keep an eye out for additional information in the near future.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
